Back

The Role of Glycan Structures in Modulating GM-CSF Bioactivity: Insights from Glycoengineering

Cagdas, E.; Skovbakke, S. L.; Agullet, J. P.; Dworkin, L. A.; Scapin, G.; Hefzi, H.; Fremming, K. S.; Schoffhelen, S.; Putkaradze, N.; Voldborg, B.; Grav, L. M.; Nielsen, L. K.; Goletz, S. G.; Lewis, N. E.

2026-02-18 bioengineering
10.64898/2026.02.17.706267 bioRxiv
Show abstract

Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a glycoprotein cytokine with therapeutic potential in cancer and neutropenia treatment. While glycosylation of GM-CSF reduces immunogenicity and enhances serum bioavailability, it can also diminish receptor binding and bioactivity. Based on transcriptomic analysis of human T lymphocytes reported previously, GM-CSF-producing cells exhibit elevated expression of Alpha-1,6-Mannosylglycoprotein 6-Beta-N-Acetylglucosaminyltransferase (MGAT5), which encodes N-acetylglucosaminyltransferase V, an enzyme involved in N-glycan branching. Given this role of MGAT5 in glycosylation, we produced GM-CSF variants using glycoengineered Chinese hamster ovary cells to generate diverse glycoforms and assessed their bioactivity. Testing their activity on TF-1 cell proliferation, we found that decreases in GM-CSF N-glycan branching significantly suppressed its activity. These findings underscore the importance of glycosylation in modulating the efficacy and safety of GM-CSF-based therapeutics, suggesting that precise glycoengineering may be key to optimizing GM-CSF performance in clinical applications.

Matching journals

The top 11 journals account for 50% of the predicted probability mass.

1
Cell Chemical Biology
81 papers in training set
Top 0.1%
12.3%
2
Nature Communications
4913 papers in training set
Top 28%
6.4%
3
Cell Reports Medicine
140 papers in training set
Top 0.4%
6.3%
4
Molecular Therapy
71 papers in training set
Top 0.5%
4.8%
5
ACS Chemical Biology
150 papers in training set
Top 0.4%
4.0%
6
Proceedings of the National Academy of Sciences
2130 papers in training set
Top 18%
4.0%
7
Cell Reports
1338 papers in training set
Top 15%
3.6%
8
Scientific Reports
3102 papers in training set
Top 37%
3.6%
9
EMBO Molecular Medicine
85 papers in training set
Top 1%
2.1%
10
Science Translational Medicine
111 papers in training set
Top 2%
2.1%
11
Science Advances
1098 papers in training set
Top 13%
2.1%
50% of probability mass above
12
Advanced Science
249 papers in training set
Top 9%
2.1%
13
iScience
1063 papers in training set
Top 10%
2.1%
14
Clinical & Translational Immunology
22 papers in training set
Top 0.1%
1.9%
15
eLife
5422 papers in training set
Top 40%
1.8%
16
JCI Insight
241 papers in training set
Top 3%
1.8%
17
Leukemia
39 papers in training set
Top 0.5%
1.8%
18
Structure
175 papers in training set
Top 2%
1.7%
19
Blood
67 papers in training set
Top 0.8%
1.7%
20
Cellular & Molecular Immunology
14 papers in training set
Top 1%
1.3%
21
Cell Genomics
162 papers in training set
Top 4%
1.2%
22
PLOS ONE
4510 papers in training set
Top 63%
0.9%
23
PNAS Nexus
147 papers in training set
Top 0.9%
0.9%
24
Bioengineering & Translational Medicine
21 papers in training set
Top 0.6%
0.9%
25
Journal for ImmunoTherapy of Cancer
64 papers in training set
Top 0.9%
0.9%
26
Journal of Clinical Investigation
164 papers in training set
Top 5%
0.9%
27
Advanced Therapeutics
15 papers in training set
Top 0.4%
0.8%
28
Cancer Research
116 papers in training set
Top 3%
0.7%
29
Cell Systems
167 papers in training set
Top 12%
0.7%
30
Cell Reports Methods
141 papers in training set
Top 5%
0.7%